Although results from Molecular Insight Pharmaceuticals Inc.'s Phase II data of Onalta (Yttrium-90 edotreotide), which showed the drug improved symptoms of metastatic carcinoid tumors in refractory patients, actually published nearly two weeks ago – and more than a month ago online – it took an after-market press release Monday to awake investors to the news. (BioWorld Today) Read More
